The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets1. Issue 1 (13th December 2012)

• Record Type: Journal Article
• Authors: Pode‐Shakked, Naomi; Shukrun, Rachel; Mark‐Danieli, Michal; Tsvetkov, Peter; Bahar, Sarit; Pri‐Chen, Sara; Goldstein, Ronald S.; Rom‐Gross, Eithan; Mor, Yoram; Fridman, Edward; Meir, Karen; Simon, Amos; Magister, Marcus; Kaminski, Naftali; Goldmacher, Victor S.; Harari‐Steinberg, Orit; Dekel, Benjamin
• Is Part Of: EMBO molecular medicine. Volume 5:Issue 1(2013:Jan.)
• Page Start: 18
• Page End: 37
• Publication Date: 2012-12-13
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.1002/emmm.201201516
• Languages: English
• ISSNs: 1757-4676

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>There are considerable differences in tumour biology between adult and paediatric cancers. The existence of cancer initiating cells/cancer stem cells (CIC/CSC) in paediatric solid tumours is currently unclear. Here, we show the successful propagation of primary human Wilms' tumour (WT), a common paediatric renal malignancy, in immunodeficient mice, demonstrating the presence of a population of highly proliferative CIC/CSCs capable of serial xenograft initiation. Cell sorting and limiting dilution transplantation analysis of xenograft cells identified WT CSCs that harbour a primitive undifferentiated – NCAM1 expressing – "blastema" phenotype, including a capacity to expand and differentiate into the mature renal‐like cell types observed in the primary tumour. WT CSCs, which can be further enriched by aldehyde dehydrogenase activity, overexpressed renal stemness and genes linked to poor patient prognosis, showed preferential protein expression of phosphorylated PKB/Akt and strong reduction of the miR‐200 family. Complete eradication of WT in multiple xenograft models was achieved with a human NCAM antibody drug conjugate. The existence of CIC/CSCs in WT provides new therapeutic targets.</p> <p>→See accompanying article <ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://dx.doi.org/10.1002/emmm.201202173</ext-link></p> </abstract>